First-Line Respiratory Support for Children With Hematologic Malignancy and Acute Respiratory Failure

Q4 Medicine
Hassaan Asif, Jennifer L. McNeer, Nancy S. Ghanayem, John F. Cursio, Jason M. Kane
{"title":"First-Line Respiratory Support for Children With Hematologic Malignancy and Acute Respiratory Failure","authors":"Hassaan Asif, Jennifer L. McNeer, Nancy S. Ghanayem, John F. Cursio, Jason M. Kane","doi":"10.1097/CCE.0000000000001076","DOIUrl":null,"url":null,"abstract":"OBJECTIVES: To characterize trends in noninvasive ventilation (NIV) and invasive mechanical ventilation (IMV) use over time in children with hematologic malignancy admitted to the PICU with acute respiratory failure (ARF), and to identify risk factors associated with NIV failure requiring transition to IMV. DESIGN: Retrospective cohort analysis using the Virtual Pediatric Systems (VPS, LLC) between January 1, 2010 and December 31, 2019. SETTING: One hundred thirteen North American PICUs participating in VPS. PATIENTS: Two thousand four hundred eighty children 0–21 years old with hematologic malignancy admitted to participating PICUs for ARF requiring respiratory support. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: There were 3013 total encounters, of which 868 (28.8%) received first-line NIV alone (NIV only), 1544 (51.2%) received first-line IMV (IMV only), and 601 (19.9%) required IMV after a failed NIV trial (NIV failure). From 2010 to 2019, the NIV only group increased from 9.6% to 43.1% and the IMV only group decreased from 80.1% to 34.2% (p < 0.001). The NIV failure group had the highest mortality compared with NIV only and IMV only (36.6% vs. 8.1%, vs. 30.5%, p < 0.001). However, risk-of-mortality (ROM) was highest in the IMV only group compared with NIV only and NIV failure (median Pediatric Risk of Mortality III ROM 8.1% vs. 2.8% vs. 5.5%, p < 0.001). NIV failure patients also had the longest median PICU length of stay compared with the other two study groups (15.2 d vs. 6.1 and 9.0 d, p < 0.001). Higher age was associated with significantly decreased odds of NIV failure, and diagnosis of non-Hodgkin lymphoma was associated with significantly increased odds of NIV failure compared with acute lymphoid leukemia. CONCLUSIONS: For children with hematologic malignancy admitted to the PICU with ARF, NIV has replaced IMV as the most common initial therapy. NIV failure rate remains high with high-observed mortality despite lower PICU admission ROM.","PeriodicalId":93957,"journal":{"name":"Critical care explorations","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical care explorations","FirstCategoryId":"0","ListUrlMain":"https://doi.org/10.1097/CCE.0000000000001076","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

OBJECTIVES: To characterize trends in noninvasive ventilation (NIV) and invasive mechanical ventilation (IMV) use over time in children with hematologic malignancy admitted to the PICU with acute respiratory failure (ARF), and to identify risk factors associated with NIV failure requiring transition to IMV. DESIGN: Retrospective cohort analysis using the Virtual Pediatric Systems (VPS, LLC) between January 1, 2010 and December 31, 2019. SETTING: One hundred thirteen North American PICUs participating in VPS. PATIENTS: Two thousand four hundred eighty children 0–21 years old with hematologic malignancy admitted to participating PICUs for ARF requiring respiratory support. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: There were 3013 total encounters, of which 868 (28.8%) received first-line NIV alone (NIV only), 1544 (51.2%) received first-line IMV (IMV only), and 601 (19.9%) required IMV after a failed NIV trial (NIV failure). From 2010 to 2019, the NIV only group increased from 9.6% to 43.1% and the IMV only group decreased from 80.1% to 34.2% (p < 0.001). The NIV failure group had the highest mortality compared with NIV only and IMV only (36.6% vs. 8.1%, vs. 30.5%, p < 0.001). However, risk-of-mortality (ROM) was highest in the IMV only group compared with NIV only and NIV failure (median Pediatric Risk of Mortality III ROM 8.1% vs. 2.8% vs. 5.5%, p < 0.001). NIV failure patients also had the longest median PICU length of stay compared with the other two study groups (15.2 d vs. 6.1 and 9.0 d, p < 0.001). Higher age was associated with significantly decreased odds of NIV failure, and diagnosis of non-Hodgkin lymphoma was associated with significantly increased odds of NIV failure compared with acute lymphoid leukemia. CONCLUSIONS: For children with hematologic malignancy admitted to the PICU with ARF, NIV has replaced IMV as the most common initial therapy. NIV failure rate remains high with high-observed mortality despite lower PICU admission ROM.
为患有血液恶性肿瘤和急性呼吸衰竭的儿童提供一线呼吸支持
目的描述因急性呼吸衰竭(ARF)入住 PICU 的血液系统恶性肿瘤患儿使用无创通气(NIV)和有创机械通气(IMV)随时间推移的趋势,并确定与 NIV 失败需要转为 IMV 相关的风险因素。设计:使用虚拟儿科系统(VPS,LLC)对 2010 年 1 月 1 日至 2019 年 12 月 31 日期间的情况进行回顾性队列分析。设置:参与 VPS 的 113 个北美 PICU。患者:2,480名0-21岁血液系统恶性肿瘤患儿,因ARF需要呼吸支持而入住参与计划的PICU。干预:无。测量和主要结果:共有 3013 次就诊,其中 868 人(28.8%)仅接受了一线 NIV(仅 NIV),1544 人(51.2%)接受了一线 IMV(仅 IMV),601 人(19.9%)在 NIV 试验失败后需要 IMV(NIV 失败)。从 2010 年到 2019 年,仅 NIV 组从 9.6% 增加到 43.1%,仅 IMV 组从 80.1% 下降到 34.2%(p < 0.001)。与仅使用 NIV 和仅使用 IMV 相比,NIV 失败组的死亡率最高(36.6% vs. 8.1%, vs. 30.5%,p < 0.001)。然而,与仅使用 NIV 和 NIV 失败组相比,仅使用 IMV 组的死亡风险 (ROM) 最高(中位儿科死亡风险 III ROM 8.1% vs. 2.8% vs. 5.5%,p < 0.001)。与其他两个研究组相比,NIV失败患者的PICU住院时间中位数也最长(15.2天 vs. 6.1天和9.0天,p < 0.001)。与急性淋巴细胞白血病相比,年龄越大发生 NIV 失败的几率越低;与非霍奇金淋巴瘤相比,诊断为非霍奇金淋巴瘤发生 NIV 失败的几率明显增加。结论:对于因急性淋巴细胞白血病入住 PICU 的血液恶性肿瘤患儿,NIV 已取代 IMV 成为最常见的初始疗法。尽管PICU入院ROM较低,但NIV失败率仍然很高,死亡率也很高。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.70
自引率
0.00%
发文量
0
审稿时长
8 weeks
文献相关原料
公司名称 产品信息 采购帮参考价格
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信